Joseph Navon, MD
Urology · Tarzana, CANPI 1871664029
Payments from drug & device makers
Across 23 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$145
- C. R. Bard, Inc. & Subsidiaries$91
- Boston Scientific$33
- Antares Pharma, Inc.$32
- GSK$27
- Richard Wolf Medical Instruments Corp.$25
- plus $152 from 8 others
What the payments were for
- Food & beverage$506100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $145 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $91 |
| Boston Scientific | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| GSK | 1 | $27 |
| Richard Wolf Medical Instruments Corp. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $23 |
| Urogen Pharma, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $19 |
| Metuchen Pharmaceuticals | 1 | $17 |
| Immunitybio, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$506 in reported general payments places this provider in the 25th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 88 | $75,232 |
| MyrbetriqMirabegron | 25 | $25,162 |
| Tamsulosin Hcl | 534 | $10,067 |
| PremarinEstrogens, Conjugated | 21 | $9,767 |
| Dutasteride | 190 | $6,987 |
| Potassium Citrate ErPotassium Citrate | 41 | $6,340 |
| Oxybutynin Chloride ErOxybutynin Chloride | 128 | $5,699 |
| Finasteride | 252 | $4,892 |
| Trospium Chloride | 62 | $4,568 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 131 | $3,399 |
| Solifenacin Succinate | 39 | $2,232 |
| Methenamine Hippurate | 14 | $1,520 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 61 | $1,510 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 28 | $1,217 |
| Silodosin | 11 | $1,195 |
Paid to pharmacies, not to this prescriber.
Other urology in Tarzana
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.